


Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension

Topouzis et al. *Eur J Ophthalmol* 2021;31:103–111


A phase 4 double-blind trial to evaluate the additive effect of brinzolamide 1% / brimonidine 0.2% fixed-dose combination on intraocular pressure in patients with open-angle glaucoma or ocular hypertension




Aim: To evaluate the additive IOP-lowering effect of twice-daily brinzolamide 1% / brimonidine 0.2% fixed dose combination (BBFC) as adjunct to PGA in people with open angle glaucoma in whom PGA alone is insufficient.





Study design



Screening and recruitment




Trial participants





Results


Target IOP of <18 mmHg achieved by:



Ocular adverse events:



Most common ocular adverse events:



Mean change in diurnal IOP, baseline to Week 6: -5.59 mmHg (95% CI: -6.2 to -5.0), BBFC + PGA; -2.15 mmHg (95% CI: -2.7 to -1.6), vehicle + PGA

Treatment difference: -3.44 mmHg (95% CI: -4.2 to -2.7; $P < 0.001$)

Conclusion

Twice-daily BBFC in addition to PGA may be a suitable treatment option for patients with open-angle glaucoma or ocular hypertension for whom PGA monotherapy is insufficient in reducing IOP. The safety profile of BBFC + PGA was consistent with the known safety profiles of brinzolamide, brimonidine, and PGAs.

Abbreviations: BBFC, brinzolamide 1%/brimonidine 0.2% fixed dose combination; CCT, central corneal thickness; IOP, intraocular pressure; OAG, open angle glaucoma; OH, ocular hypertension; PGA, prostaglandin analogue
Topouzis F, Goldberg I, Bell K, Tatham AJ, Ridolfi A, Hubatsch D, et al. *Eur J Ophthalmol* 2021;31:103–111.

This content has been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.